CT-based radiomics and deep learning to predict EGFR mutation status in lung adenocarcinoma
Frontiers in Oncology · 02.10.2025 · 15
DOI: 10.3389/fonc.2025.1597548 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 02.10.2025. Verfasst von Xingzhi Jiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, the First People's Hospital of Yancheng, Yancheng, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Epidermal growth factor receptor (EGFR) mutation status is an essential biomarker guiding targeted therapy selection in lung adenocarcinoma. This study aimed to develop and validate a non-invasive predictive model that integrates radiomics and deep learning using CT images for accurate assessment of EGFR mutation status.
Methods
A total of 220 patients with lung adenocarcinoma were retrospectively enrolled and randomly divided into training and testing cohorts at a 7:3 ratio. Radiomics features were extracted from CT images using PyRadiomics, and deep learning features were obtained from five pretrained architectures: ResNet34, ResNet152, DenseNet121, ShuffleNet, and Vision Transformer (ViT). Feature selection used the intraclass correlation coefficient, Spearman correlation, and LASSO regression. The deep learning architectures were compared within the training set using cross-validation, and the best-performing architecture, ViT, was retained for downstream modeling. Based on the selected features, we constructed a radiomics model (Rad model), a ViT-based deep learning model (ViT model), and two fusion models (early fusion and late fusion) integrating radiomics and ViT features. Model performance was evaluated using receiver operating characteristic (ROC) curves, area under the curve (AUC), accuracy, sensitivity, specificity, precision, F1-score, and decision curve analysis (DCA).
Results
The fusion models outperformed both radiomics and deep learning models in predicting EGFR mutation status. In the testing set, the early fusion model achieved the highest predictive performance (AUC = 0.910), exceeding the late fusion model (AUC = 0.892), the ViT model (AUC = 0.870), and the Rad model (AUC = 0.792). It also demonstrated superior accuracy (0.848), sensitivity (0.872), and specificity (0.815). Decision curve analysis further confirmed its clinical utility.
Conclusion
Our study demonstrated that integrating radiomics and deep learning contributed to EGFR mutation prediction, providing a non-invasive approach to support personalized treatment decisions in lung adenocarcinoma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory Medicine, the First People's Hospital of Yancheng, Yancheng, China.
- The Yancheng Clinical College of Xuzhou Medical University, Yancheng, China.
- Department of Pulmonary and Critical Care Medicine, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu, China.
- Department of Radiology, the First People's Hospital of Yancheng, Yancheng, China.
- Yancheng No.1 People's Hospital, Affiliated Hospital of Medical School, Nanjing University, Yancheng, China.
Zitieren
APA
Jiang, X., Sun, Q., Wang, C., Li, W., Chen, W., Xu, J., & Yu, L. (2025). CT-based radiomics and deep learning to predict EGFR mutation status in lung adenocarcinoma. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1597548
Vancouver
Jiang X, Sun Q, Wang C, Li W, Chen W, Xu J, et al. CT-based radiomics and deep learning to predict EGFR mutation status in lung adenocarcinoma. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1597548
BibTeX
@article{Jiang2025,
author = {Jiang, Xingzhi and Sun, Qian and Wang, Can and Li, Wei and Chen, Wang and Xu, Juan and Yu, Lei},
title = {CT-based radiomics and deep learning to predict EGFR mutation status in lung adenocarcinoma},
journal = {Frontiers in Oncology},
year = {2025},
volume = {15},
doi = {10.3389/fonc.2025.1597548}
}
EUVIMED